Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO Sells $3,752,459.34 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO William Richard White sold 139,083 shares of Akero Therapeutics stock in a transaction that occurred on Wednesday, July 24th. The stock was sold at an average price of $26.98, for a total transaction of $3,752,459.34. Following the transaction, the chief financial officer now directly owns 41,791 shares in the company, valued at approximately $1,127,521.18. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

William Richard White also recently made the following trade(s):

• On Tuesday, July 16th, William Richard White sold 34,811 shares of Akero Therapeutics stock. The shares were sold at an average price of $28.04, for a total value of $976,100.44.
• On Tuesday, June 11th, William Richard White sold 2,831 shares of Akero Therapeutics stock. The shares were sold at an average price of $22.64, for a total value of $64,093.84.

Akero Therapeutics Stock Performance

Shares of NASDAQ AKRO opened at $28.12 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 30.12 and a quick ratio of 30.12. The firm has a market cap of $1.94 billion, a price-to-earnings ratio of -8.79 and a beta of -0.28. The stock’s fifty day moving average price is $22.98 and its two-hundred day moving average price is $22.99. Akero Therapeutics, Inc. has a one year low of $11.25 and a one year high of $53.77.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings results on Friday, May 10th. The company reported ($0.90) EPS for the quarter, meeting the consensus estimate of ($0.90). On average, equities analysts forecast that Akero Therapeutics, Inc. will post -3.82 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Headlands Technologies LLC acquired a new stake in shares of Akero Therapeutics in the 4th quarter valued at $28,000. Russell Investments Group Ltd. boosted its stake in Akero Therapeutics by 2,366.0% in the first quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock valued at $31,000 after buying an additional 1,183 shares in the last quarter. Quarry LP grew its position in Akero Therapeutics by 40.0% in the fourth quarter. Quarry LP now owns 1,750 shares of the company’s stock valued at $41,000 after acquiring an additional 500 shares during the last quarter. Strs Ohio raised its stake in Akero Therapeutics by 100.0% during the fourth quarter. Strs Ohio now owns 2,000 shares of the company’s stock worth $46,000 after acquiring an additional 1,000 shares in the last quarter. Finally, Quest Partners LLC acquired a new position in Akero Therapeutics during the fourth quarter worth about $75,000.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on AKRO shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Akero Therapeutics in a research report on Thursday, June 20th. Wolfe Research initiated coverage on shares of Akero Therapeutics in a report on Tuesday, June 11th. They issued an “outperform” rating on the stock. HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Akero Therapeutics in a report on Tuesday, June 11th. Canaccord Genuity Group dropped their target price on Akero Therapeutics from $59.00 to $56.00 and set a “buy” rating on the stock in a report on Monday, May 13th. Finally, Evercore ISI decreased their price target on Akero Therapeutics from $50.00 to $38.00 and set an “outperform” rating for the company in a research note on Wednesday, May 15th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $41.13.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.